TELA Bio (TELA) Gains from Investment Securities (2018 - 2019)
TELA Bio (TELA) posted quarterly Gains from Investment Securities of $1000.0 for Q4 2019, up 101.89% year-over-year from $495.33 in Q4 2018, and up 102.94% quarter-over-quarter from -$34000.0 in Q3 2019.
TELA Bio (TELA) Gains from Investment Securities (2018 - 2019) Analysis & Trends
TELA Bio's Gains from Investment Securities history runs 2 years deep, the most recent figure standing at $1000.0 for Q4 2019.
- In Q4 2019, Gains from Investment Securities rose 101.89% year-over-year to $1000.0; the TTM figure through Dec 2022 stood at -$33000.0 (changed N/A YoY), while the FY2025 annual figure was $888000.0, changed 0.11% from the prior year.
- Gains from Investment Securities for Q4 2019 stood at $1000.0, up from -$34000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $74000.0 in Q2 2019, with the low at -$53000.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.63 Bn | 194.02 Bn | 7.27 Bn |
| 2 | Stryker | 127.42 Bn | 123.95 Bn | 4.50 Bn |
| 3 | Medtronic | 118.97 Bn | 109.75 Bn | 6.41 Bn |
| 4 | Boston Scientific | 73.39 Bn | 72.85 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.97 Bn | 47.72 Bn | 1.35 Bn |
| 6 | Dexcom | 34.32 Bn | 32.37 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn |
| 9 | Steris | 23.04 Bn | 22.56 Bn | 684.20 Mn |
| 10 | TELA Bio | 36.24 Mn | 5.82 Mn | 13.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 1,000.00 |
| Dec 31, 2019 | 1,000.00 |
| Sep 30, 2019 | -34,000.00 |
| Sep 30, 2019 | -34,000.00 |
| Jun 30, 2019 | 74,000.00 |
| Jun 30, 2019 | 74,000.00 |
| Mar 31, 2019 | -36,000.00 |
| Mar 31, 2019 | -36,000.00 |
| Dec 31, 2018 | -53,000.00 |
| Dec 31, 2018 | -53,000.00 |
| Sep 30, 2018 | -17,000.00 |
| Sep 30, 2018 | -17,000.00 |